Future Perspectives for the Development of Chemotherapy for Advanced Gastric Cancer: Japanese and Global Status

被引：2
|
作者：
Higuchi, Katsuhiko [1 ]
Tanabe, Satoshi [1 ]
Azuma, Mizutomo [1 ]
Sasaki, Tohru [1 ]
Ishido, Kenji [1 ]
Koizumi, Wasaburo [1 ]
机构：
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, Sagamihara, Kanagawa 2520380, Japan
来源：
PATHOBIOLOGY | 2011年 / 78卷 / 06期
关键词：
Gastric cancer; Chemotherapy; Molecular target agent; Personalized therapy; PHASE-III TRIAL; ADVANCED ESOPHAGOGASTRIC CANCER; S-1 PLUS CISPLATIN; 1ST-LINE TREATMENT; FLUOROURACIL; DOXORUBICIN; METHOTREXATE; CAPECITABINE; OXALIPLATIN; MITOMYCIN;
D O I：
10.1159/000321700
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
In Japan, gastric cancer is the second leading cause of cancer-related mortality after lung cancer. Many randomized trials of various chemotherapeutic regimens have been conducted, contributing to improved outcomes in patients with advanced gastric cancer (AGC). The standard regimen for AGC is a combination of S-1 and cisplatin in Japan. Recently, new drug development has focused on molecular target agents, and personalized therapy for AGC has just begun. In patients with human epidermal growth factor receptor 2-positive AGC, trastuzumab in combination with chemotherapy improves survival. Furthermore, abundant information about the heterogeneity and biological backgrounds of AGC patients has been compiled. New strategies for the development of personalized therapy should be studied in the future. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：334 / 342
页数：9
相关论文
共 50 条
  • [21] Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives
    Terashima, Masanori
    Yoshikawa, Takaki
    Boku, Narikazu
    Ito, Seiji
    Tsuburaya, Akira
    Iwasaki, Yoshiaki
    Fukagawa, Takeo
    Tokunaga, Masanori
    Sano, Takeshi
    Sasako, Mitsuru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 528 - 534
  • [22] Evolving chemotherapy for advanced gastric cancer
    Ajani, JA
    ONCOLOGIST, 2005, 10 : 49 - 58
  • [23] Weekly Paclitaxel as Second-line Chemotherapy in Japanese Patients with Advanced Gastric Cancer
    Kadokura, Makoto
    Iwasa, Satoru
    Honma, Yoshitaka
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Enomoto, Nobuyuki
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2013, 33 (10) : 4547 - 4552
  • [24] New perspectives in the treatment of advanced or metastatic gastric cancer
    Rosati, Gerardo
    Ferrara, Domenica
    Manzione, Luigi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (22) : 2689 - 2692
  • [25] Global chemotherapy development for gastric cancer
    Kazuto Harada
    Dilsa Mizrak Kaya
    Yusuke Shimodaira
    Jaffer A. Ajani
    Gastric Cancer, 2017, 20 : 92 - 101
  • [26] Advanced gastric cancer:Current treatment landscape and future perspectives
    Antonia Digklia
    Anna Dorothea Wagner
    World Journal of Gastroenterology, 2016, (08) : 2403 - 2414
  • [27] Global chemotherapy development for gastric cancer
    Harada, Kazuto
    Kaya, Dilsa Mizrak
    Shimodaira, Yusuke
    Ajani, Jaffer A.
    GASTRIC CANCER, 2017, 20 : S92 - S101
  • [28] Current status and future perspectives on neoadjuvant therapy in gastric cancer
    Ao, Sheng
    Wang, Yuchen
    Song, Qingzhi
    Ye, Yingjiang
    Lyu, Guoqing
    CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (02) : 181 - 191
  • [29] Management of advanced gastric cancer. Current status and future therapeutic strategies
    Lorenzen, S.
    Lordick, F.
    ONKOLOGE, 2013, 19 (05): : 389 - 394
  • [30] Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives
    Scartozzi, Mario
    Bittoni, Alessandro
    Pistelli, Mirco
    Galizia, Eva
    Berardi, Rossana
    Giampieri, Riccardo
    Faloppi, Luca
    Cascinu, Stefano
    CANCER TREATMENT REVIEWS, 2009, 35 (05) : 451 - 462
12345